Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance [0.03%]
中国城镇职工基本医疗保险制度下监管竞争对医药价格的影响分析
Mingyue Zhao,Jing Wu
Mingyue Zhao
Background: Examine the effects of regulated competition on the drug pricing in China. Methods: Based on product-level data, a regressi...
Taehwan Park,Chang-Ju Choi,Yeera Choi et al.
Taehwan Park et al.
Cetuximab is a novel biological agent with superior therapeutic efficacy for colorectal cancer treatment. This study aimed to systematically review the existing evidence related to the cost-effectiveness of cetuximab. Areas covered: Using M...
Hepatitis C: how has France limited the expenses related to new treatments? [0.03%]
法国如何限制与新型药物治疗丙型肝炎相关的费用？
Anne-Laure Mouterde,François Bocquet,Isabelle Fusier et al.
Anne-Laure Mouterde et al.
The impact of comorbidities on costs, utilities and health-related quality of life among HIV patients in a clinical setting in Bogotá [0.03%]
并存疾病对波哥大临床环境中HIV患者成本、效用及健康相关生活质量的影响
Mark Jm Van Duin,Rafael Conde,Ben Wijnen et al.
Mark Jm Van Duin et al.
Background: This study aimed to assess the impact of comorbidities (CMs) on costs, utilities and health-related quality of life (HRQOL) among HIV patients in Colombia. ...
A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis [0.03%]
维多珠单抗治疗中至重度活动性溃疡性结肠炎的成本效益分析的综述研究
Her Hsin Tsai,Christopher Black
Her Hsin Tsai
Vedolizumab is a novel humanised monoclonal IgG1 antibody gut selective anti-integrin specifically targeting α4β7 integrins in the gut and found to be efficacious in the treatment of ulcerative colitis. Areas covered: Research investigati...
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C [0.03%]
索磷布韦维帕他韦治疗慢性丙型肝炎患者的报告结果和经济成果分析
Linda Henry,Zobair Younossi
Linda Henry
We used published literature from 2013-2016, to review data regarding the new all oral interferon and ribavirin free direct acting antiviral (DAA's) treatment regimens. Areas covered: Specifically, this paper will address DAA's clinical eff...
Corrigendum [0.03%]
勘误表
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland [0.03%]
芬兰重度抑郁症治疗切换至沃西汀与阿戈美拉丁、盐酸安非他酮缓释片、sertraline和文拉法辛缓释片的费用效用分析研究
Erkki Soini,Taru Hallinen,Mélanie Brignone et al.
Erkki Soini et al.
Background: To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the finnish setting in major depressive disorder (MDD) patients with inadeq...
Carl Rudolf Blankart,Ricarda Milstein,Meike Rybczynski et al.
Carl Rudolf Blankart et al.
Marfan syndrome is a rare multisystem disease of the connective tissue, which affects multiple organ systems. advances in healthcare have doubled the life-expectancy of patients over the past three decades. to date, there is no comprehensiv...
A scoping review of pediatric economic evaluation 1980-2014: do trends over time reflect changing priorities in evaluation methods and childhood disease? [0.03%]
1980-2014年儿科经济学评价的范围性综述：历时趋势反映评价方法和儿童疾病优先次序的变化吗？
Shannon M Sullivan,Kate Tsiplova,Wendy J Ungar
Shannon M Sullivan
Economic evaluations conducted in children have unique features compared to adults. Important developments in pediatric economic evaluation in recent years include new options for valuing health states for cost-utility analysis (CUA) and sh...